Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Neuroblastoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive, Peripheral 1Melanoma 1Hepatoblastoma 1Head and Neck Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Gastrointestinal Neoplasms 1Ependymoma 1Central Nervous System Neoplasms 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Radiosurgery 22Nivolumab 21Ipilimumab 19pembrolizumab 15Temozolomide 11dabrafenib 10binimetinib 10encorafenib 8Cyclophosphamide 8trametinib 7Magnetic Resonance Spectroscopy 7Bevacizumab 6fludarabine 5cobimetinib 5Specimen Handling 5CTLA-4 Antigen 5fludarabine phosphate 3aldesleukin 3Vemurafenib 3Thalidomide 3Paclitaxel 3Oxaliplatin 3Interleukin-2 3Gemcitabine 3Drug Therapy 3Carboplatin 3130-nm albumin-bound paclitaxel 3ulixertinib 2tovorafenib 2relatlimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × MLN 8237 × CNS × Clear all
NCT01639911 2019-07-22

Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors

University of Illinois at Chicago

Phase 1 Completed
28 enrolled
BreastCNSDermatologicGastrointestinalHead & Neck

Breast Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Melanoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡